News Headlines

OncoGenex Increases Economic Interest in Lead Cancer Drug OGX-011
04 July 2008
Under the amended agreement between OncoGenex and Isis, the former will be solely responsible for all future development activities related to OGX-011.

MS Drug Development Agreement Based on WEHI's Medicinal Chemistry
03 July 2008
Research conducted at the institute has contributed to a major licensing agreement signed between Bionomics and Merck Serono.

Bayer HealthCare and Maxygen Announce Hematology Agreement
03 July 2008
The $120 million transaction includes license to Maxygen’s novel biotechnology research platform.

Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
02 July 2008
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.

Galapagos Signs new Compound Management Agreement with Sepracor
01 July 2008
Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library.

Cellumen to Collaborate with the NCTR of the FDA to Apply Cellular Systems Biology to Predictive Toxicology
01 July 2008
Cellumen will use its proprietary CellCiphr® toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds.

Millipore Unveils Expanded Drug Discovery Development Facility
30 June 2008
The $3.4 million expansion will enable Millipore to keep pace with the growth of its worldwide drug discovery and development business.

Eden Biodesign Confirms Research Triangle Park Facility
26 June 2008
The Company expands US operation to offer a range of cell line/strain development and early process development services.